BOSTON & SAN DIEGO, July 6, 2026
Vertex Pharmaceuticals has announced a definitive agreement to acquire Crinetics Pharmaceuticals in an all-cash transaction valued at approximately $10 billion, significantly expanding its portfolio of endocrine disease therapies and strengthening its long-term growth strategy. The acquisition brings together Crinetics’ commercial product PALSONIFY® (paltusotine), the first and only once-daily oral therapy approved for adults with acromegaly, along with the late-stage investigational candidate atumelnant, currently in Phase 3 clinical development for congenital adrenal hyperplasia (CAH). The transaction, unanimously approved by both companies’ boards of directors, is expected to close during the third quarter of 2026, subject to customary regulatory approvals and shareholder approval. The acquisition reinforces Vertex’s commitment to developing transformative medicines for serious diseases while expanding its presence in the growing endocrine therapeutics market.
Vertex Strengthens Rare Endocrine Disease Portfolio
The acquisition represents one of the largest pharmaceutical transactions of 2026 and positions Vertex to accelerate commercialization of PALSONIFY®, which has already demonstrated strong early market adoption following its U.S. FDA approval in September 2025 and subsequent approval by the European Medicines Agency (EMA). PALSONIFY offers a significant advancement in acromegaly treatment by providing the first once-daily oral alternative to injectable somatostatin analog therapies. Vertex believes its global commercial infrastructure and experience in launching therapies for rare diseases will further expand patient access and maximize the product’s commercial potential.
The company also expects the acquisition to enhance its innovation pipeline while supporting its objective of maintaining sustained double-digit revenue growth over the coming years. According to Vertex, the combined commercial opportunity from PALSONIFY and atumelnant could exceed $5 billion in annual peak sales, making the acquisition strategically significant for both revenue growth and long-term shareholder value.
Phase 3 Atumelnant Adds Transformative Pipeline Potential
Advertisement
A major highlight of the acquisition is atumelnant, an investigational once-daily oral ACTH receptor antagonist currently advancing through Phase 3 clinical trials for classic congenital adrenal hyperplasia (CAH). The therapy has demonstrated the potential to normalize excess androgen production while allowing patients to remain on physiologic glucocorticoid doses, addressing one of the most challenging aspects of current CAH management. Clinical studies have shown encouraging efficacy and a favorable safety profile, while additional development is underway for ACTH-dependent Cushing’s syndrome, further expanding its commercial opportunity. Beyond these late-stage assets, Crinetics contributes a robust pipeline of more than ten endocrine-focused development programs, including therapies targeting GPCR biology, GLP-1, GIP, thyroid stimulating hormone, parathyroid hormone, and neuroendocrine tumors.
Vertex expects the acquisition to become accretive to non-GAAP operating income by 2029 and will finance the transaction through a combination of existing cash reserves and committed bridge financing. The deal reflects continued consolidation across the biotechnology industry as major pharmaceutical companies pursue innovative late-stage assets capable of addressing significant unmet medical needs while strengthening future growth pipelines.
Source: Vertex Pharmaceuticals, Crinetics Pharmaceuticals press release
